SoftMaxx AI sells no peptides and takes no vendor money.
Human RCT The larger of the two palmitoyl pentapeptide trials cited here tested pal-KTTKS, which its abstract calls palmitoyl pentapeptide: in a randomized, double-blind split-face trial, 93 women used a moisturizer containing it at the trial concentration (see the doses table) on one side of the face and the same moisturizer without it on the other for 12 weeks, and fine lines and wrinkles improved significantly more on the peptide side. A smaller 8-week randomized trial split 21 women in all between a palmitoyl pentapeptide-4 (PPP-4) cream, an acetylhexapeptide-3 cream and placebo, and the PPP-4 cream did better than both.[1][2]
The peptide and its sequence
Pal-KTTKS, the compound in the 93-woman trial, is a five-amino-acid peptide (Lys-Thr-Thr-Lys-Ser, KTTKS) with a fatty-acid (palmitoyl) tail, used in anti-wrinkle creams [1][3]. The KTTKS sequence comes from type I procollagen, the collagen precursor [4], and pal-KTTKS was designed as a topical agent to stimulate collagen production [1]. A 2011 review notes relatively few clinical studies of it [3].
The palmitic-acid tail makes it more stable than plain KTTKS and lets more of it into the skin, at least in mouse skin tests [5].
The smaller trial tested a palmitoyl pentapeptide-4 (PPP-4) cream; its abstract does not give the compound's amino-acid sequence [2].
- In vitro (cells) In fibroblast cultures the KTTKS fragment is the minimal sequence that stimulates type I and III collagen and fibronectin production. Palmitoylation makes it more stable and lets measurable amounts reach the epidermis and dermis in mouse skin, whereas unmodified KTTKS did not penetrate.[4][5][3]
Claims vs. evidence
Each popular claim, graded by the strongest study behind it. The words in quotation marks are how the claim is marketed; the text after the grade is what the studies show.
- Claim as marketed
Reduces fine lines and wrinkles
Human RCT A 12-week split-face randomized trial (n=93) of pal-KTTKS was positive. In a small 8-week randomized trial (n=21 across three arms), a palmitoyl pentapeptide-4 cream did better than an acetylhexapeptide-3 cream and placebo. Neither abstract reports how large the improvement was.[1][2] - Claim as marketed
Boosts collagen production
In vitro (cells) Collagen stimulation was measured in cultured fibroblasts. The two human trials measured wrinkles (image analysis, expert grading, photos) and, in the smaller one, skin hydration and elasticity; neither abstract reports a collagen measurement.[4][1][2] - Claim as marketed
General topical peptide anti-aging benefit
Expert review A 2026 meta-analysis of 19 randomized trials of oral and topical peptides found a modest pooled wrinkle effect, largely driven by oral polypeptides. Effects on elasticity and density were inconsistent.[6]
Common myths, checked
- Common belief
Matrixyl is proven to rebuild collagen in your face.
In vitro (cells) Collagen stimulation by the KTTKS sequence was shown in cell culture. The pal-KTTKS trial (93 women) measured wrinkles and fine lines by image analysis and expert grading, and the palmitoyl pentapeptide-4 trial (21 women across three arms) used photos, grading and skin hydration and elasticity readings; neither abstract reports a collagen measurement.[4][1][2] - Common belief
Matrixyl is a copper peptide.
Expert review We found no cited abstract that describes copper in either trial compound: pal-KTTKS is palmitoyl-lysine-threonine-threonine-lysine-serine [1], whose KTTKS sequence comes from type I procollagen [4], and the other trial names palmitoyl pentapeptide-4 [2].[3][4][1][2] - Common belief
Matrixyl works as well as tretinoin.
No supporting study We found no head-to-head trial of Matrixyl against tretinoin. The two palmitoyl pentapeptide trials cited here compared a moisturizer with pal-KTTKS against the same moisturizer without it, and a palmitoyl pentapeptide-4 cream against an acetylhexapeptide-3 cream and placebo; neither tested tretinoin.[1][2]
Doses used in studies (not a recommendation)
Each row comes from the cited source: a study dose, a safety-review limit or a registered trial's planned dose, as labelled. Where the abstract states no amount, the row says so. They are a record of what was reported, not dosing instructions, and nothing here says what you should take.
| Studied in | Route | Amount reported | How often | How long | n | Source |
|---|---|---|---|---|---|---|
| Humans | topical moisturizer, split-face | 3 ppm pal-KTTKS in a moisturizer (the trial concentration) Study dose | not stated in abstract | 12 weeks | 93 | [1] 93 Caucasian women aged 35–55 with photoaged skin; double-blind, placebo-controlled, split-face |
| Humans | topical cream to periorbital area | not stated in abstract Study dose | twice daily | 8 weeks | 21 | [2] 21 Indonesian women aged 26–55 in all, split across 3 arms |
Side effects and risks
- Human RCT pal-KTTKS: well tolerated by the skin in the 93-person, 12-week trial[1]
Regulatory status (checked 2026-10-01 to 2026-10-03)
- United States (FDA)We found no FDA-approved product containing palmitoyl pentapeptide-4 in Drugs@FDA (searched 2026-10-01). (FDA:
Drugs@FDA search: matrixyl — no approved product found
, captured 2026-10-01) Under the FD&C Act, cosmetic products and ingredients, with the exception of color additives, do not require FDA approval before they go on the market; the Act defines drugs, in part, by their intended use, including “articles (other than food) intended to affect the structure or any function of the body of man or other animals”, and some products meet the definitions of both cosmetics and drugs. (FDA:Is It a Cosmetic, a Drug, or Both?
, captured 2026-10-03) - CanadaWe found no product containing palmitoyl pentapeptide-4 in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada:
Health Canada Drug Product Database search: matrixyl — no product found
, captured 2026-10-01) - Sport (WADA)WADA’s Prohibited List does not name palmitoyl pentapeptide-4. WADA states that topical cosmetic products may contain prohibited peptides or growth factors and that using cosmetic products containing such substances is prohibited; we found no WADA statement on whether palmitoyl pentapeptide-4 is one of them. (WADA:
World Anti-Doping Code International Standard Prohibited List 2026
, captured 2026-10-03; WADA:The Prohibited List
, captured 2026-10-03)
Official sources: FDA: Is It a Cosmetic, a Drug, or Both?
· WADA: World Anti-Doping Code International Standard Prohibited List 2026
· WADA: The Prohibited List
Report a side effect
If something went wrong after using a health product, tell a clinician. Report side effects to:
- FDA MedWatch (United States)
- Health Canada (report a side effect)
Common questions
Does Matrixyl work?
Human RCT In the larger trial cited here, 93 women used a moisturizer with pal-KTTKS on one side of the face for 12 weeks, and fine lines and wrinkles improved significantly more than with the same moisturizer without it [1]. In a smaller 8-week trial, 21 women in all were split between a palmitoyl pentapeptide-4 cream, an acetylhexapeptide-3 cream and placebo, and the palmitoyl pentapeptide-4 cream did better than both [2]. Its abstract names the peptide only as palmitoyl pentapeptide-4, without a sequence, so it may not have been pal-KTTKS, the compound PubChem lists as Matrixyl.[1][2]
Is Matrixyl a copper peptide?
Expert review We found no cited abstract that describes copper in either trial compound: pal-KTTKS is palmitoyl-lysine-threonine-threonine-lysine-serine [1], whose KTTKS sequence comes from type I procollagen [4], and the other trial names palmitoyl pentapeptide-4 [2].[3][4][1][2]
References
Every reference below was matched to its PubMed or DOI record (title checked) before publication. "Verified" means the paper exists and is the one named; what it supports is stated next to each claim.
Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin.
PubMed 18492182 DOIDouble-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet.
PubMed 36909866Topically applied KTTKS: a review.
PubMed 21535443 DOIA pentapeptide from type I procollagen promotes extracellular matrix production.
PubMed 8486721 DOIDermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS).
PubMed 25143811 DOIOral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials.
PubMed 41924746 DOI
Keep reading
- Best peptides for skin, ranked by evidence→
- Copper peptides vs retinol: what the evidence shows→
- Peptides for looksmaxxing: what the evidence actually shows→
- GHK-Cu (copper tripeptide-1): what the evidence shows→
- Argireline (acetyl hexapeptide-8): what the evidence shows→
- Matrixyl 3000 (contains palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7): what the evidence shows→
- All peptide pages, by evidence→